SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · Adults with COPD
1 finding from 1 review
FEV1 · Adults with COPD
1 finding from 1 review
Difference vs placebo in adjusted peak FEV1 (3‐week to 6‐month · Adults with COPD
1 finding from 1 review
Six‐minute walk distance · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH
1 finding from 1 review
PAP · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
Cardiac index · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
PVR · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
Intervention not reported
SAEs ‐ formoterol versus placebo ( · patients with chronic asthma
The intervention leads to higher SAEs ‐ formoterol versus placebo ( (high certainty).
1 finding from 1 review
Intervention not reported
Mortality (all‐cause) ‐ formoterol versus placebo ( · patients with chronic asthma
The intervention showed no clear difference in mortality (all‐cause) ‐ formoterol versus placebo ( (moderate certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ formoterol versus placebo ( · patients with chronic asthma (children)
The intervention leads to higher SAEs ‐ formoterol versus placebo ( (high certainty).
1 finding from 1 review
Annual Exacerbation Rates · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Pneumonia · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS may leads to higher pneumonia compared with placebo (low certainty).
1 finding from 1 review
Oropharyngeal candidiasis · patients with stable chronic obstructive pulmonary disease
Summary of findings table ‐ ICS probably leads to higher oropharyngeal candidiasis compared with placebo (moderate certainty).
1 finding from 1 review
Participants with no exacerbations in study period · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant probably leads to higher number of participants with no exacerbations during the study period compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Respiratory‐related mortality · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in mortality (respiratory‐related) compared with placebo (low certainty).
1 finding from 1 review